CAR-T细胞(ZUMA-1)对比挽救性化疗治疗难治性大B细胞淋巴瘤的2年结局比较
本研究通过倾向性评分匹配,将ZUMA-1研究中101例接受axi-cel治疗的可评估患者与SCHOLAR-1国际回顾性研究中434例可评估疗效、424例可评估生存的难治性大B细胞淋巴瘤患者进行2年结局比较。结果显示,ZUMA-1组客观缓解率和完全缓解率分别为83%和54%,SCHOLAR-1组分别为34%和12%;2年生存率分别为54%和20%,ZUMA-1组死亡风险降低73%。尽管为非随机对照分析,结果提示axi-cel较非CAR-T挽救方案可产生持久缓解和显著生存获益。
要点
- ZUMA-1组2年生存率54%,SCHOLAR-1组20%,死亡风险降低73%。
- ZUMA-1组ORR 83%、CR率54%,SCHOLAR-1组分别为34%和12%。
- ZUMA-1患者既往治疗更密集,仍显示持久缓解和生存优势。
核心结论
- 对于难治性大B细胞淋巴瘤,axi-cel较非CAR-T挽救方案产生持久缓解和显著生存获益。
研究设计与样本
- ZUMA-1为关键1/2期研究(NCT02348216),其中2期部分101例接受axi-cel并可评估疗效和生存,中位随访27.1个月。
- SCHOLAR-1为国际回顾性研究,434例可评估疗效、424例可评估生存。
- 比较前采用基于广泛预后协变量的倾向性评分使两组达到平衡。
主要发现
- ZUMA-1组客观缓解率为83%、完全缓解率为54%;SCHOLAR-1组分别为34%和12%。
- ZUMA-1组2年生存率为54%,SCHOLAR-1组为20%。
- ZUMA-1组较SCHOLAR-1组死亡风险降低73%。
- ZUMA-1患者既往治疗较SCHOLAR-1患者更密集。
- 另有一项标准化分析将分层限于2个预后因素(难治性分类和化疗难治后有无干细胞移植)以保留样本量,结果与主分析一致。
临床怎么用
- 对于难治性大B细胞淋巴瘤,axi-cel可作为较非CAR-T挽救化疗带来持久缓解和生存获益的治疗选择。
局限性
- 分析为非随机比较,存在非随机化分析的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and survival among patients with refractory large B-cell lymphoma (LBCL) treated with conventional chemotherapy. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated durable responses in patients with refractory LBCL in the pivotal phase 1/2 ZUMA-1 study (NCT02348216). Here, we compared SCHOLAR-1 with the 2-year outcomes of ZUMA-1. Prior to comparison of clinical outcomes, propensity scoring (based on a broad set of prognostic covariates) was used to create balance between ZUMA-1 and SCHOLAR-1 patients. In the pivotal phase 2 portion of ZUMA-1, 101 patients received axi-cel and were evaluable for response and survival. In SCHOLAR-1, 434 and 424 patients were evaluable for response and survival, respectively. ZUMA-1 patients were more heavily pretreated than were SCHOLAR-1 patients. The median follow-up was 27.1 months in ZUMA-1. The objective response rate (ORR) and complete response rate were 83% and 54% in ZUMA-1 vs 34% and 12% in SCHOLAR-1, respectively. The 2-year survival rate was 54% in ZUMA-1 and 20% in SCHOLAR-1, and a 73% reduction in the risk of death was observed in ZUMA-1 vs SCHOLAR-1. These results were consistent with those of an additional standardization analysis in which strata were limited to 2 prognostic factors (refractory categorization and presence/absence of stem cell transplant after refractoriness to chemotherapy) to conserve sample size. Despite the limitations of a nonrandomized analysis, these results indicate that axi-cel produces durable responses and a substantial survival benefit vs non-CAR T-cell salvage regimens for patients with refractory LBCL.
引用
- Neelapu SS, Locke FL, Bartlett NL, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021. PMID: 34478487. doi:10.1182/bloodadvances.2020003848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。